Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat serious endocrinologic, oncologic, metabolic and neurologic diseases by modulating the effects of the hormone cortisol, today announced the publication of results from the prevalence phase of the CATALYST study in Diabetes Care , a peer-reviewed journal of the American Diabetes Association.
